First introduced in Europe in 1971, but voluntarily withdrawn in 1975 after it was shown to cause agranulocytosis.
1989: studies demonstrated more effective than any other antipsychotic so approved for treatment-resistant schizophrenia.
Patients have FBC (full blood count) monitored weekly for first 18 weeks, then 2 weeks for rest of year, 4 weeks for ever after.
Severe side effects:
- PE and diabetes
- sialorrhea (hypersalivation)
- constipation and weight gain